XML 36 R23.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Schedules of Concentration of Risk, by Risk Factor
A significant customer is any biopharmaceutical customer, clinical testing payer, or international laboratory partner that represents 10% or more of the Company’s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company’s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company’s total accounts receivable balance, at the respective condensed consolidated balance sheet date, are as follows:
Revenue
Accounts Receivable, Net
Three Months Ended
September 30,		Nine Months Ended
September 30,		September 30,
2025		December 31,
2024
2025202420252024
(unaudited)(unaudited)
Customer A
*****14 %
Customer B
29 %28 %29 %29 %13 %12 %
Customer C
****10 %11 %
*    less than 10%
Schedule of Disaggregation of Revenue
The following table presents the Company’s revenue disaggregated by revenue source:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
(unaudited)
(in thousands)
Oncology$184,402 $141,197 $493,646 $397,214 
Biopharma and data
54,731 46,547 156,127 128,067 
Screening24,112 1,003 44,603 1,003 
Licensing and other
1,951 2,729 6,379 10,918 
Total revenue
$265,196 $191,476 $700,755 $537,202